The NOR-SWITCH Study

Summary

The NOR-SWITCH Study is a clinical trial^[1].

Key Facts

• The NOR-SWITCH Study is in the country of Norway^[2].
• The NOR-SWITCH Study's instance of is recorded as clinical trial^[3].
• The NOR-SWITCH Study's start time is recorded as +2014-10-31T00:00:00Z^[4].
• The NOR-SWITCH Study's end time is recorded as +2016-06-30T00:00:00Z^[5].
• The NOR-SWITCH Study's sponsor is recorded as Diakonhjemmet Hospital^[6].
• The NOR-SWITCH Study's main subject is recorded as psoriasis^[7].
• The NOR-SWITCH Study's main subject is recorded as arthritis^[8].
• The NOR-SWITCH Study's main subject is recorded as colitis^[9].
• The NOR-SWITCH Study's number of participants is recorded as {'unit': '1', 'amount': '+482'}^[10].
• The NOR-SWITCH Study's title is recorded as A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY^[11].
• The NOR-SWITCH Study's short name is recorded as NOR-SWITCH^[12].
• The NOR-SWITCH Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[13].
• The NOR-SWITCH Study's ClinicalTrials.gov ID is recorded as NCT02148640^[14].
• The NOR-SWITCH Study's research intervention is recorded as infliximab^[15].
• The NOR-SWITCH Study's clinical trial phase is recorded as phase IV clinical trial^[16].
• The NOR-SWITCH Study's research site is recorded as Diakonhjemmet Hospital^[17].
• The NOR-SWITCH Study's research site is recorded as University of Oslo^[18].
• The NOR-SWITCH Study's research site is recorded as Betanien Hospital^[19].
• The NOR-SWITCH Study's study type is recorded as interventional study^[20].